Hi TVs,I was a bit confused by the ParmAIa projections here....

First 753 Last

Share
Profile

Follow
malkazoid

1,235 Posts.

1543

28/04/23

11:16

Post #: 67501693
Share

Originally posted by thevinnys: ↑

Australia Commercial Market Forecast

● MDMA-Assisted Psychotherapy is expected to cost ~$15-20k AUD per 3-month course of treatment, however, drug costs are anticipated to represent only ~$1500 of the total costs.
● Psilocybin Therapy is likely to cost ~$5K per 3-day course of treatment, with treatments recurring at 3 or 6-month intervals. Drug costs per treatment are not expected to exceed $500.
● It is highly likely that therapy components will be reimbursable by numerous entities, while drug costs are likely to remain out-of-pocket for the foreseeable future.
● As additional competitors enter the Commercial market with viable drug products, PharmAla anticipates price compression of 50% per annum for the period 2023-26. PharmAla also anticipates significant cost reductions in the manufacture of its drug products, allowing absorption of price compression without a significant effect on profitability.

Approximately 250,000-500,000 individuals are diagnosed with PTSD in Australia on an annual basis; In 2021, 1.45m Australians were diagnosed as having PTSD.1 Assuming a conservative 50% takeup rate of MDMA-assisted psychotherapy treatments, we assess an initial market of ~700,000 patients in Year 1, and ~150,000 patients on an ongoing annual basis.

● Approximately 1.17m Australians suffer from Depressive Episodes as of 2021.1 Assuming a higher 65% takeup rate of Psilocybin Therapy due to lower therapist costs, we assess an initial market of ~750,000 patients and an annual patient market of~150,000 patients.

● The major rate-limiting factor affecting the number of patients that can be treated under the July 1 TGA guidance will be the number of authorized prescribers at any given time. However, each authorized prescriber represents a significant number of additional patients, as prescribers can be supported by additional therapists to execute treatments.

https://pharmala.ca/assets-documents/PharmAla-Company-Background-Q2-2023-APRIL.pdf

Some big numbers possible for our Clarion Clinics GLAH

Expand

Hi TVs,

I was a bit confused by the ParmAIa projections here. They are using a base figure of 1.17 million sufferers of depressive episodes, but only a portion of these would be treatment resistant and the TGA only allows psilocybin to be prescribed for treatment resistant depression. Why are they not taking this into account, do you reckon?

IHL Price at posting: 12.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The winners & losers on market if negative gearing were gone

There are more pages in this discussion • 478 more messages in this thread...

First 753 Last

Add IHL (ASX) to my watchlist

Hi TVs,I was a bit confused by the ParmAIa projections here....

Top Stories

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ACCC seeks Olam divestments before it can buy Namoi Cotton

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The winners & losers on market if negative gearing were gone

Featured News